Bisphosphonates (BP) are first-line treatment for women with post-menopausal osteoporosis (PMO), with denosumab (Dmab) recommended second-line [1]. Recent recommendations mention long-term discontinuation (LTD) of BP, particularly in women with low fracture risk who have received treatment for 3 to 5 years [1, 2]. A recent study of US administrative claims data (2006-2016) from 81,427 women aged ≥ 65 years reported 28% of those treated with BP had LTD, which was associated with an increased risk of fracture (from 22% to 59% depending on fracture site and BP drug) [3]. However, data regarding LTD of BPs and/or Dmab in Europe is lacking.